mizoribine has been researched along with puromycin aminonucleoside in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gomi, H; Ishimoto, F; Matsuda, H; Sakai, O; Shibasaki, T; Usui, M | 1 |
| Bessho, F; Hagiwara, E; Kawakami, H; Khoshnoodi, J; Kurayama, R; Nakajo, A; Sekine, Y; Swiatecka-Urban, A; Takahashi, S; Takenaka, H; Tryggvason, K; Watanabe, T; Yan, K | 1 |
| Hiromura, K; Kaneko, Y; Kuroiwa, T; Maeshima, A; Nojima, Y; Sakairi, T; Takahashi, S; Takeuchi, S; Tomioka, M | 1 |
3 other study(ies) available for mizoribine and puromycin aminonucleoside
| Article | Year |
|---|---|
Mizoribine reduces urinary protein excretion in rats given puromycin aminonucleoside.
Topics: Animals; Antibiotics, Antineoplastic; Immunosuppressive Agents; Male; Nephrosis; Nephrosis, Lipoid; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Wistar; Ribonucleosides; Thromboxane B2 | 1996 |
Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance.
Topics: Adenosine Triphosphate; Animals; Cells, Cultured; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Energy Metabolism; Humans; Immunosuppressive Agents; IMP Dehydrogenase; Intracellular Membranes; Kidney Glomerulus; Male; Membrane Proteins; Membrane Transport Proteins; Mice; Nephrotic Syndrome; Podocytes; Protein Processing, Post-Translational; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; Ribonucleosides; RNA, Messenger; Stress, Physiological | 2007 |
The immunosuppressive drug mizoribine directly prevents podocyte injury in puromycin aminonucleoside nephrosis.
Topics: Animals; Immunosuppressive Agents; IMP Dehydrogenase; Male; Membrane Proteins; Nephrosis; Podocytes; Protein Serine-Threonine Kinases; Puromycin Aminonucleoside; Rats; Rats, Wistar; Ribonucleosides | 2010 |